MRI-guided Transurethral Ultrasound Ablation, or TULSA, is a novel MRI-guided procedure that uses therapeutic ultrasound effectively treats prostate cancer with minimal side effects.
How is TULSA performed?
TULSA is a minimally invasive procedure that, under MRI guidance, delivers precise doses of therapeutic ultrasound to treat prostate cancer while sparing the healthy nerve tissue surrounding the prostate.
TULSA relies on a rod-shaped device that is inserted into the urethra. The novel device has 10 ultrasound-generating elements that can cover the entire prostate gland. One or more of the elements are used to send out sound waves that heat and destroy the target prostate tissue. The elements are controlled automatically by a software algorithm that can adjust the shape, direction and strength of the therapeutic ultrasound beam. The entire procedure takes place in an MRI scanner so that doctors can closely monitor treatment and assess the degree and location of heating.
"Unlike with other ultrasound systems on the market, you can monitor the ultrasound ablation process in real time and get immediate MRI feedback of the thermal dose and efficacy," said study co-author Steven S. Raman, M.D., professor of radiology and urology, and director of Prostate MR Imaging and Interventions and Prostate MR Imaging Research at the University of California at Los Angeles (UCLA).
What happens after the TULSA procedure?
Patients generally go home the same day.
What are the benefits of TULSA?
Compared with other treatment options, TULSA offers many benefits:
Are you a candidate for TULSA?
If you are interested in seeing if you are a candidate for TULSA, please contact our IR clinic at 310-481-7545, option 1 to arrange an appointment with one of our IR physicians.
For the clinical trial study utilizing TULSA, please review on our clinical trials page
A prospective, multi-center, single-arm study, planned in 110 patients. The primary objective of the study is to further evaluate the safety and efficacy of a magnetic resonance imaging (MRI)-guided transurethral ultrasound therapy system (TULSA-PRO) intended to ablate prostate tissue of patients with localized, organ-confined prostate cancer.
If interested, please check out the eligibility criteria on ClinicalTrials.gov
ClinicalTrials.gov identifier: NCT03527589
Contact: Tammy Floore, BSN, MBA, 310-794-9202, [email protected]Principal Investigator:Steven Raman, MD, FSAR, FSIR